Tag: GlobeNewswire

• Study demonstrates feasibility of saline-based hybrid IVUS-OCT imaging without iodinated contrast during image acquisition
• FDA-cleared OCTIV system now in commercial clinical use, with patient cases ongoing

TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company developing imaging technologies to guide cardiovascular procedures, today announced the presentation of data from its OCTIV™ hybrid IVUS–OCT imaging system at Transcatheter Cardiovascular Therapeutics (“TCT”) 2026. The study, conducted in an animal model before OCTIV’s use in patients, demonstrated the feasibility of using saline instead of iodinated contrast during image acquisition. The FDA-cleared system is now in commercial clinical use, with its first U.S. placement completed and patient cases ongoing. The findings were presented by Megha Prasad, MD, MS, in an abstract titled “Saline-Based Hybrid IVUS-OCT Imaging: Feasibility of Contrast-Free Dual-Modality Intracoronary Imaging in a Porcine Model.”

“These findings highlight the potential of OCTIV to provide complementary ultrasound and optical images using saline, eliminating the need for iodinated contrast during image acquisition,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “Since this study was conducted, OCTIV has advanced into commercial clinical use, with our first U.S. placement completed and patient cases ongoing. We are pleased to share these results as we build clinical experience with the system.”

Study Results

The prospective feasibility study evaluated hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging of major coronary arteries in three swine, using saline as the sole OCT flushing medium. Investigators performed 26 imaging pullbacks in native vessels and following stent placement, assessing feasibility, safety, catheter performance and image quality.

Key findings included:

• Interpretable images across all 26 pullbacks: Hybrid imaging was successfully performed in all targeted vessels without iodinated contrast during image acquisition.
• Complementary vessel assessment: OCT provided high-resolution visualization of luminal morphology and stent architecture, while IVUS enabled assessment of vessel dimensions and deeper wall structures within the same pullback.
• Continuous IVUS imaging: IVUS assessment remained available independently of blood clearance, with high-resolution OCT visualization achieved when saline flushing was adequate.
• No observed device-related complications: No device-related complications, coronary injury, sustained arrhythmia or procedural mortality occurred.
• Potential to eliminate iodinated contrast during image acquisition: The findings support further clinical evaluation of saline-based hybrid imaging, which could be particularly relevant for patients at risk of contrast-associated acute kidney injury.  

About Conavi Medical
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented OCTIV hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit http://www.conavi.com/.

Forward-Looking Statements
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the anticipated clinical benefits and performance of OCTIV, continued clinical use, placements at additional U.S. institutions, participation in TCT 2026, the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact
Mark Quick, Chief Financial Officer | 416-483-0100
Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com
Susan Thomas, Media | 619-540-9195

Seasonal Initiative Builds on Established Relationship with Leading Regional Grocery Retailer

BELVIDERE, NJ, Nov. 03, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that it has secured a fresh herb program with Weis Markets for the upcoming 2026 holiday season. Building on its established relationship with the regional grocery retailer, the program provides an opportunity for Edible Garden to increase seasonal sales while reinforcing its position as a trusted supplier of fresh, high-quality herbs throughout the Mid-Atlantic region.

The holiday program builds on Edible Garden’s established relationship with Weis Markets, which includes fresh potted living herbs, hydroponic basil, and cut herb varieties. With consumer demand for fresh culinary herbs typically increasing around Thanksgiving and the December holidays, the seasonal program provides an additional opportunity to support Weis Markets’ customers during one of the most important selling periods for the category. Edible Garden’s established distribution infrastructure and proximity to Weis Markets’ core markets position the Company to respond efficiently to seasonal demand while maintaining its focus on product freshness, quality, and sustainability.

“Securing this holiday program with Weis Markets reflects the strength of our relationship and our ability to support retail partners during critical selling periods,” said Jim Kras, Chief Executive Officer of Edible Garden. “We have worked to establish Edible Garden as a reliable supplier by consistently delivering the quality, freshness, and service our retail customers expect. With our Belvidere facility strategically located near Weis Markets’ core markets, we believe we are well positioned to meet increased holiday demand while maintaining the efficiency and sustainability that distinguish our operations. This program also presents an opportunity to generate incremental sales and further demonstrate the value of our regional growing and distribution capabilities.”

The Weis Markets holiday program highlights the importance of Edible Garden’s established retail partnerships in supporting its long-term growth strategy. As the Company continues to build its presence in the fresh herb category, seasonal programs such as this provide opportunities to increase sales, deepen customer relationships, and strengthen its competitive position in key regional markets.

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believe,” “expect,” “intend,” “plan,” “expand,” “advance,” “designed to,” “opportunity,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements include, without limitation, statements regarding the Company’s holiday fresh herb program with Weis Markets, the Company’s ability to expand its presence and capture additional market share in its key markets, the Company’s available capacity and ability to service additional retail volume, the Company’s ability to deepen its relationship with Weis Markets and other major retailers, and the Company’s Farm-to-Formula® strategy. There can be no assurance that the holiday program or the Company’s distribution center awards will result in the anticipated volume, revenue or market share gains. Forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including those described in the “Risk Factors” section and other sections of the Company’s reports filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com

Decades of experience growing dual-use defense technology companies 

Trusted senior intelligence leader, with a record of accomplishment across strategic, tactical and policy roles

Former CEO of Constellis and Tenax Aerospace, global leaders in applied geospatial technology

DENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in geospatial intelligence powered by proprietary 3D data, rapid image processing software and AI-driven analytics, today announced the appointment of Mr. Terry Ryan to its Board of Directors.

Mr. Ryan brings decades of experience in geospatial intelligence as a former federal official and defense and intelligence executive. Mr. Ryan served as a corporate senior executive of high-growth public and private defense technology companies, including Science Applications International Corp. (SAIC), the predecessor of Leidos Holdings, Inc., ManTech, Mercury Systems, VT Services, SRA International and Tenax Aerospace, all of which provide or provided geospatial-related support services to federal customers.

Mr. Ryan has advised past directors of the CIA, the Joint Chiefs of Staff and the Defense Advanced Research Projects Agency (DARPA) on advanced GEOINT solutions. As a former professional staff member of the U.S. Senate and House Intelligence oversight committees, Director, Intelligence Surveillance and Reconnaissance Systems, Office of Secretary of Defense and Deputy Director of the Defense Airborne Reconnaissance Office, Mr. Ryan has overseen the allocation of billions of dollars to develop and integrate airborne and spaceborne multi-domain sensor platforms. Most recently, as CEO and director of Constellis corporation, Mr. Ryan led the development of Constellis’ LEXSO, a layered AI decision-support platform that integrates multi-domain sensor data on geospatial foundational layers to enhance real-time situational awareness for the protection of critical infrastructure, globally. This appointment supports Intermap’s continued investment in integrating its global-scale airborne and spaceborne GEOINT across multi-domain operations. Mr. Ryan continues to support Constellis’ global operations and deployment of the LEXSO platform as Executive Vice Chairman.

“We are delighted to welcome Terry to Intermap’s Board as we expand our multi-domain product suite,” said Patrick A. Blott, Chairman and Chief Executive Officer of Intermap Technologies. “Terry has built and led world-class defense technology companies, focused on deploying integrated sensor capabilities in space, air, land and sea to produce autonomous geospatial intelligence. His deep relationships across government and institutional investors will strengthen Intermap as we pursue new opportunities around the world.”

“Intermap has built a differentiated geospatial intelligence platform that integrates sensors to address critical latency and autonomy challenges for government and commercial customers,” said Terry Ryan. “The Company has established a strong foundation for growth, combining proprietary global-scale 3D terrain data with advanced spaceborne image processing and AI decision support. I look forward to working with the Board and management team to help advance Intermap’s strategy, broaden access to growth capital and create long-term value for shareholders.”

To facilitate the appointment of Mr. Ryan to the Board of Directors of Intermap prior to the next annual meeting of shareholders, Mr. Philippe Frappier has graciously agreed to step down as a director of Intermap and will continue as a Board observer and advisor during the interim period. It is expected that Mr. Frappier will be nominated for election with the existing directors of Intermap at the next annual meeting of shareholders.

Intermap Reader Advisory 
Certain information contained in this news release, including statements regarding Mr. Ryan’s anticipated contributions to the Company, the expected benefits of his appointment and the Company’s growth opportunities, constitutes forward-looking information or forward-looking statements under applicable securities laws. Words such as “anticipate,” “expect,” “project,” “estimate,” “forecast,” “will,” “may,” “intend,” “plan,” “believe” and similar expressions are intended to identify forward-looking statements. Although Intermap believes these statements are based on information and assumptions that are current, reasonable and complete, they are necessarily subject to a variety of known and unknown risks and uncertainties. Intermap’s forward-looking statements are subject to risks and uncertainties relating to, among other matters, cash available to fund operations, access to capital, revenue fluctuations, the nature of government contracts, economic conditions, the loss of key customers, the retention and availability of executive talent, competing technologies, common-share price volatility, the loss of proprietary information, software functionality, internet and systems infrastructure, information technology security, the breakdown of strategic alliances and international and political considerations. Additional risks and uncertainties are discussed in Intermap’s Annual Information Form and other securities filings. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those anticipated. Accordingly, no assurance can be given that the events or results contemplated by the forward-looking statements will occur. All forward-looking statements attributable to Intermap or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. The forward-looking statements in this news release are made as of its date, and the Company undertakes no obligation to update or revise them publicly, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

About Intermap Technologies
Intermap Technologies is a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics. The Company delivers actionable intelligence to government and commercial customers through a portfolio of applications, platforms and solutions that support risk management, infrastructure planning, operational readiness and mission-critical decision-making. Intermap’s proprietary 3D data foundation spans more than 300 million square kilometers across over 150 countries and powers intelligence solutions for government, insurance, aviation, telecommunications, transportation, renewable energy, agriculture, natural resources and space markets. Through advanced analytics, automated processing and enterprise-scale data delivery, Intermap helps organizations transform complex geospatial information into decision-ready intelligence.

For more information, please visit www.intermap.com or contact:
Jennifer Bakken
Executive Vice President and CFO
CFO@intermap.com
+1 (303) 708-0955

Sean Peasgood
Investor Relations
Sean@SophicCapital.com
+1 (647) 260-9266

LOUISVILLE, Ky., Nov. 03, 2026 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended September 30, 2026 before the market open on Monday, November 16, 2026. A conference call to review the results is scheduled for Monday, November 16, 2026, at 9:00 am Eastern Time, which will include prepared remarks and materials from management followed by a live Q&A. The call will be hosted by Rick Mills, Chairman and Chief Executive Officer, Tamra Koshewa, Chief Financial Officer and George Sautter, Chief Strategy Officer.

Prior to the call, participants should register at https://bit.ly/CREXearnings3Q2026. Once registered, participants can use the weblink provided in the registration email to participate in the live webcast.  An archived edition of the earnings conference call will be posted on our website and will remain available for one year.

About Creative Realities, Inc.
Creative Realities designs, develops and deploys digital signage-based experiences for enterprise-level networks utilizing its Clarity™, ReflectView™, and iShowroom™ Content Management System (CMS) platforms. The Company is actively providing recurring SaaS and support services across diverse vertical markets, including but not limited to retail, automotive, digital-out-of-home (DOOH) advertising networks, convenience stores, foodservice/QSR, gaming, theater, and stadium venues. In addition, the Company assists clients in utilizing place-based digital media to achieve business objectives such as increased revenue, enhanced customer experiences, and improved productivity. This includes the design, deployment, and day to day management of Retail Media Networks to monetize on-premise foot traffic utilizing its AdLogic™ and AdLogic CPM+™ programmatic advertising platforms.

Cautionary Note on Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and includes, among other things, discussions of our business strategies, product releases, future operations and capital resources. Words such as “estimates,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Forward-looking statements are not guarantees of future performance, conditions or results. They are based on the opinions, estimates and beliefs of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties, assumptions and other factors, many of which are outside of our control, that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Some of these risks are discussed in the “Risk Factors” section contained in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s subsequent filings with the U.S. Securities and Exchange Commission. Important factors, among others, that may affect actual results or outcomes include: our ability to integrate the acquired business operations of Cineplex Digital Media Inc. (“CDM”) into our own, maintain or improve the financial performance of CDM’s business and realize anticipated synergies, our strategy for customer retention, growth, product development, market position, financial results and reserves, our ability to execute on our business plan, our ability to retain key personnel, our ability to remain listed on the Nasdaq Capital Market, our ability to realize the revenues included in our future guidance and backlog reports, our ability to satisfy our upcoming debt obligations and other liabilities, the ability of the Company to continue as a going concern, potential litigation, supply chain shortages, and general economic and market conditions impacting demand for our products and services. Readers should not place undue reliance upon any forward-looking statements. We assume no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

Media:
Idea Grove
creativerealities@ideagrove.com

Investor Relations:
Chris Witty, Darrow Associates
646-438-9385
cwitty@darrowir.com

ir@cri.com
https://investors.cri.com

PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), along with one BridgeBio-supported poster presentation led by Abbott Laboratories, will be shared at the American Heart Association (AHA) Scientific Sessions 2026, taking place in Chicago, Illinois on November 6-9, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

Acoramidis is approved as Attruby® by the U.S. FDA and is approved as BEYONTTRA® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, the Brazilian Health Regulatory Agency (ANVISA), and the Australian Therapeutic Goods Administration (TGA) with all labels specifying near-complete stabilization of TTR.

Moderated Posters:
Bridging the Diagnostic Gap in Transthyretin Cardiac Amyloidosis (ATTR-CM): Enhancing ATTR-CM Detection at the Time of Heart Failure Diagnosis in Women Through Sex-Specific ATTR Models (SS-ATTR-CMs)
Presenter: Hyewon Jeong, M.D., M.S., Massachusetts Institute of Technology, U.S.
Date/time: Monday, November 9 at 9:50 am CT

Artificial Intelligence for the Screening of ATTR Cardiomyopathy in the U.S.: A Multicenter Analysis from the TRACE-AI Network
Presenter: Bruno Batinica, MBChB, Yale School of Medicine, U.S.
Date/time: Monday, November 9 at 11:20 am CT

Posters:
Effects of Acoramidis on Heart Failure Events in Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM
Presenter: Mazen Hanna, M.D., Cleveland Clinic, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Risk of Multiple Cardiovascular-Related Hospitalizations and of All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy: Findings from ATTRibute-CM Using Multistate Modeling
Presenter: Justin L. Grodin, M.D., UT Southwestern Medical Center, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Recovery After Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights from an N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Analysis of the ATTRibute-CM Study
Presenter: Prem Soman, M.D., University of Pittsburgh Medical Center, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Abbott Laboratories-Led, BridgeBio-Supported Poster Presentation:
Detection of Tetrameric Transthyretin by ARCHITECT c and Alinity c Assays
Presenter: Lici A. Schurig Briccio, Ph.D., Abbott Laboratories, U.S.
Date/time: Monday, November 9 at 9:36 am CT

About Attruby® (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650) 789-8220

BridgeBio Investor Contact:
BridgeBio Investor Relations
ir@bridgebio.com

Foremost receives proceeds of $650,000 and retains 20% interest in GR and Blackwing properties, with 6-month grace period for initial JV expenditures

VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”) is pleased to report that it has closed a transaction with Denison Mines Corp. (“Denison”) resulting in, among other things, the sale of a 31% interest in the GR and Blackwing properties (together, the “Properties”), the formation of two exploration joint ventures (“JVs”), and the issuance of 1,031,191 share purchase warrants (the “Warrants”) in exchange for total cash consideration of $650,000 (collectively, the “Transaction”). The Warrants have an exercise price of $1.80 per warrant share, which represents over a 175% premium to Foremost’s closing share price on October 22, 2026, the date on which the Transaction was announced, and have a 5-year term.

David Cates, Interim CEO of Foremost, commented, “The GR and Blackwing properties are located in the northwestern portion of the Athabasca Basin region and are situated along the Grease River shear zone and the Black Bay fault, respectively – both of which are geologically prospective areas that have historically been subject to little or no exploration and that have the potential to become new areas of exploration focus in the region. Forming the GR and Blackwing joint ventures with Denison is an ideal arrangement for Foremost, whereby the Company receives $650,000 in cash proceeds while retaining exposure to potential future exploration success from the Properties without having to fund the full cost of exploration. Importantly, the proceeds from the Transaction are expected to be used largely to fund Foremost’s recently commenced exploration program at the Turkey Lake property.”

GR & Blackwing Highlights

• Foremost and Denison have formed two exploration JVs, with Foremost holding a 20% ownership interest in each of the Properties.
• The GR property consists of 16 mineral claims covering 78,585 hectares, and the Blackwing property consists of 3 mineral claims covering 12,627 hectares (see Figure 1).
• Denison is responsible for funding its share of future expenditures (currently 80%), per the JV agreements, and has committed to either carry out geophysical studies or make deficiency deposits to maintain the Properties until at least January 4, 2028 (the “Initial Expenditures”).
• Foremost expects Denison will carry out geophysical studies within the next 12 months to further define the exploration potential of the Properties and generate future drill targets.
• Foremost has the option to decide, within 6 months of the earlier of the completion of the initial geophysical surveys and the date of the last of the Initial Expenditures, to (i) fund its share of the Initial Expenditures or (ii) dilute its ownership pursuant to the terms of the JVs.

Figure 1. GR & Blackwing Properties

Warrant Terms

• Foremost issued 1,031,191 Warrants to Denison with an exercise price of $1.80 per warrant share and a term of 5 years (the “Term”). The number of Warrants exercisable by Denison at any time is limited to such number of Warrants that, if exercised, would not result in Denison’s ownership of Foremost exceeding 19.95% (the “Ownership Cap”).
• The exercise price of $1.80 represents over a 175% premium to Foremost’s closing share price of $0.64 on October 22, 2026, the date on which the Transaction was announced.
• At maturity, if exercise of any remaining Warrants would result in the holder exceeding the Ownership Cap, then Foremost will either (a) apply for and obtain an extension of the Term of the Warrants for such duration as may be approved by the Canadian Securities Exchange, or (b) purchase from the holder any remaining Warrants not exercisable due to the Ownership Cap based on the differential between the exercise price and the current market price for each warrant share.
• The Warrants are subject to a four-month hold period expiring on March 3, 2027 and thereafter will be transferable.

Amended & Restated Option Agreement

• The Option Agreement entered into between Denison and Foremost on September 23, 2024 (the “Original Option Agreement”) included 10 properties and has been amended and restated (the “A&R Option Agreement”) to exclude the Properties such that Foremost no longer has any right to increase its ownership interest in those two Properties.
• Accordingly, any subsequent expenditures incurred by Foremost in connection with the Properties will be governed by the applicable JV agreements and will not count towards satisfaction of Option Tranche 3 under, and as defined in, the A&R Option Agreement.
• The A&R Option Agreement preserves Foremost’s right to complete Option Tranche 3 and earn an additional 19% interest (for an aggregate interest of 70%) in 7 of the remaining 8 properties under option from Denison and a minimum 51% interest in Hatchet Lake, by (i) completing $12.0 million in eligible exploration expenditures on the remaining 8 properties by July 9, 2029, and (ii) paying Denison $2.5 million in additional consideration in cash, common shares of Foremost or a combination thereof.
• The full details of the A&R Option Agreement will be available under Foremost’s profile on SEDAR+ at www.sedarplus.ca.

Amended & Restated Investor Rights Agreement

• The amended and restated investor rights agreement between Denison and Foremost dated July 23, 2025, was further amended and restated to make certain other amendments of a housekeeping or administrative nature (the “Second A&R Investor Rights Agreement”).

Early Warning Requirements

Immediately prior to entry into the A&R Option Agreement, the Second A&R Investor Rights Agreement, and the acquisition of the Warrants, Denison owned or controlled 3,448,610 common shares of Foremost, representing approximately 19.9% of the issued and outstanding shares, and held 607,600 share purchase warrants to acquire an additional 607,600 shares, representing approximately 15.2% of the outstanding share purchase warrants of Foremost.

As a result of the acquisition of the Warrants, Denison owns or controls 3,448,610 common shares of Foremost, representing approximately 19.9% of the issued and outstanding shares and holds 1,638,791 share purchase warrants to acquire an additional 1,638,791 common shares, representing approximately 32.6% of the outstanding share purchase warrants of Foremost. The Warrants are subject to a restriction that Denison shall not be entitled to exercise any Warrants to the extent that, after giving effect to such exercise, Denison would beneficially own or exercise control or direction over more than 19.95% of the issued and outstanding Foremost shares at the time of exercise.

This press release and Denison’s corresponding early warning report (the “Early Warning Report”), which is expected to be filed on SEDAR+ in the near term, constitute the required disclosure pursuant to section 5.2 of National Instrument 62-104 – Take-Over Bids and Issuer Bids (“NI 62-104”). The Early Warning Report is being filed in connection with a change in material fact contained in Denison’s last early warning report dated July 9, 2026. The Warrants acquired by Denison pursuant to the foregoing transactions are being acquired for investment purposes. Denison may from time to time acquire additional securities, dispose of some or all of the existing or additional securities, or may continue to hold the securities of Foremost.

The Early Warning Report that will be filed on SEDAR+ in respect of the A&R Option Agreement, the Second A&R Investor Rights Agreement, and the Warrants will satisfy the requirement of section 5.2 of NI 62-104 to have the Early Warning Report filed by an acquiror, with the securities regulatory authorities in each of the jurisdictions in which Foremost is a reporting issuer and which contains the information required by section 3.1 of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which includes the information required by Form 62-103F1.   A copy of the Early Warning Report will be available under Foremost’s profile on SEDAR+ at www.sedarplus.ca.

Qualified Person

The technical content of this news release has been reviewed and approved by Cameron MacKay, P. Geo., Vice President of Exploration for Foremost Clean Energy Ltd., and a Qualified Person under National Instrument 43-101.

About Foremost

Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (WKN: A3DCC8) is a North American uranium, lithium, and gold exploration company strategically positioned to support the long-term growth in demand expected for reliable, carbon-free energy sources.

The Company has a portfolio of 10 property interests spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan, including an option from Denison to earn up to a 70% interest in 7 prospective uranium properties and a minimum 51% interest in the Hatchet Lake property, plus a minority ownership interest (20%) in the GR & Blackwing joint ventures with Denison.

The Company’s uranium exploration efforts benefit from access to extensive historic drilling and geophysical data for targeting high-potential, mineralized trends. To date, Foremost has completed geophysical surveys and multiple drill campaigns that have generated encouraging results and defined high-priority exploration targets for follow-up drilling.

Foremost also has a portfolio of lithium-focused projects at varying stages of development spanning 43,000+ acres in Manitoba, providing exposure to other critical materials essential in electrification and energy storage.

For further information, please visit the Company’s website at www.foremostcleanenergy.com.

Contact and Information

David Cates, Interim CEO
info@foremostcleanenergy.com

Investor Relations
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-REDCHIP (733-2447)
FMST@redchip.com

Follow us or contact us on social media:
X: @fmstcleanenergy
LinkedIn: https://www.linkedin.com/company/foremostcleanenergy  
Facebook: https://www.facebook.com/ForemostCleanEnergy

Forward-Looking Statements

Except for the statements of historical fact contained herein, the information presented in this news release and oral statements made from time to time by representatives of the Company are or may constitute “forward-looking statements” as such term is used in applicable United States and Canadian laws and including, without limitation, within the meaning of the Private Securities Litigation Reform Act of 1995, for which the Company claims the protection of the safe harbor for forward-looking statements. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates” or “intends,” or stating that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements include, among others, statements with respect to: the expected use of the proceeds from the Transaction, including to fund the Company’s recently commenced exploration program at the Turkey Lake property; the Company maintaining its 20% interest in each of the Properties; Denison funding 80% of future expenditures and carrying out geophysical studies or making deficiency deposits to maintain the Properties until at least January 4, 2028; the expectation that Denison will carry out geophysical studies within the next 12 months and that such studies will further define the exploration potential of the Properties and generate future drill targets; the potential for the Properties to become a new area of exploration focus and the Company’s exposure to potential future exploration success; the Company’s election to fund its share of the Initial Expenditures or dilute its ownership interest; the exercise of the Warrants; the application of the Ownership Cap and any extension of the Term or purchase by the Company of Warrants not exercisable due to the Ownership Cap; the Company’s ability to complete Option Tranche 3 under the A&R Option Agreement, including completing $12.0 million in eligible exploration expenditures by July 9, 2029 and paying $2.5 million in additional consideration to Denison; the availability of the A&R Option Agreement on SEDAR+; filing of the Early Warning Report, including the timing thereof; and the long-term growth in demand expected for carbon-free energy sources.

In making the forward-looking statements in this news release, the Company has applied several material assumptions, including, without limitation, that: the proceeds from the Transaction will be used as currently anticipated; Denison will perform its obligations under the joint venture agreements, the Warrants and the A&R Option Agreement; geophysical studies on the Properties will be carried out as expected and will yield results supporting further exploration; the Company will have access to sufficient capital, on acceptable terms, to fund its exploration programs, its share of joint venture expenditures (if it so elects) and the requirements of Option Tranche 3; the market price of the Company’s common shares will not change in a manner that adversely affects the Warrants or the Company’s obligations relating to the Ownership Cap; any required approval of the Canadian Securities Exchange for an extension of the Term will be obtained in a timely manner; there will be no material adverse change in uranium prices, general economic, market or industry conditions; and exploration and permitting activities will not be materially delayed by weather, regulatory or other factors.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release include, among others: the risk that the proceeds from the Transaction are used other than as currently anticipated or are insufficient to fund the Company’s planned exploration at the Turkey Lake property; the risk that Denison does not carry out geophysical studies or other expenditures on the Properties as anticipated, or that such studies do not identify drill targets or further define exploration potential; the inherent uncertainty of mineral exploration and the speculative nature of exploration-stage properties; the dilution of the Company’s interest in the joint ventures should it elect not to, or be unable to, fund its share of expenditures; the risk that the Company is required to purchase Warrants from Denison or that an extension of the Term is not approved; the potential dilution to shareholders resulting from the exercise of the Warrants; the Company’s inability to complete Option Tranche 3 or to fund the required expenditures and additional consideration under the A&R Option Agreement, and the consequences of any default thereunder; the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares; continuity of agreements with third parties, including Denison; fluctuations in uranium and other commodity prices and in the market price of the Company’s common shares; risks and uncertainties associated with the environment; and delays in obtaining governmental approvals, permits or financing. Additional factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission.

Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities. Please refer to the Company’s most recent filings under its profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov for further information respecting the risks affecting the Company and its business.

The CSE has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3a1f9c96-0fc8-4675-a11e-92ca714cf9a5

Drilling and Trenching Integrated with Airborne Geophysics to Refine Further Exploration Targets in Botswana

TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) — One Bullion Ltd. (TSXV: OBUL) (“One Bullion” or the “Company”), a gold exploration company holding complete ownership of three prospective exploration projects in Botswana, today announced a consolidated summary of historical drilling and trenching results from its wholly owned Vumba Gold Project in Botswana, along with an update on ongoing exploration work. The historical results which have not been previously disclosed in the Company’s news releases. They form part of the exploration database now being integrated with airborne geophysics and geological information from the 2026 drilling program.

“The historical results at Vumba provide an important addition to our understanding of the project and reinforce the exploration potential we see across the property,” said Adam Berk, Chief Executive Officer of One Bullion. “By bringing together previously undisclosed drilling and trenching results with our 2026 exploration data and airborne geophysics, we are building a more complete picture of the project’s gold mineralization and identifying opportunities to advance the highest-priority targets. We believe this integrated approach will help us deploy exploration capital more efficiently, focus future drilling on the most prospective areas and continue building value for shareholders.”

The consolidated data highlights gold mineralization at surface and in drilling, and places those results within the regional geological setting. The Company is integrating these historical results with its 2026 drilling data and airborne geophysics to better define the geological controls on mineralization, refine priority exploration targets and identify opportunities for follow-up drilling to evaluate the potential extensions and continuity of gold mineralization.

Highlights

• Reverse circulation drilling returned 26.0 m at 2.60 g/t gold in SR033 and 28.0 m at 1.47 g/t gold in SR083.
• Diamond hole SD071 returned 13.0 m at 8.52 g/t gold, including 1.0 m at 101.81 g/t gold. The composite is strongly influenced by this one-meter sample.
• One Bullion’s diamond drilling returned 1.0 m at 20.90 g/t gold in VUDD005 and 1.0 m at 15.25 g/t gold in VUDD016.
• Trench VUT004 returned 3.5 m at 18.79 g/t gold, including 2.5 m at 26.12 g/t gold, providing additional evidence of gold mineralization at surface.

Drill intervals are downhole lengths and trench intervals are sampled lengths along the trench. True widths have not been established.

Building on the Exploration Record

Vumba has progressed from surface prospecting and sampling of old workings to systematic soil sampling, trenching, reverse circulation and diamond drilling, and ground and airborne geophysics. That work has established a series of gold-bearing positions with differing grades and interval lengths. The 2026 program adds geological observations and a higher-resolution geophysical framework against which the earlier results can be assessed.

The regional setting also provides useful context. Gold mining in the Gwanda and Tati greenstone belts demonstrates the occurrence of gold deposits in the broader southern Zimbabwe Craton. At Vumba, the exploration case rests on the results obtained on the property and the opportunity to test the geological controls on those results.

Regional Gold Mines and the Vumba Setting

Vumba lies within the greenstone terrain of the southern Zimbabwe Craton in northeastern Botswana. Across the wider region, the Gwanda belt in Zimbabwe hosts Blanket, Vubachikwe, Jessie, Freda and Farvic, while the Tati belt in Botswana includes Mupane, Golden Eagle, Map Nora and Signal Hill. These are separate greenstone belts containing gold deposits in a range of host-rock and structural settings. Figure 1 locates these mines and deposits relative to Vumba and One Bullion’s Maitengwe project. [1–4]

Published resource estimates and historical production accounts illustrate the mining history and range of deposits in the region. Blanket’s June 2026 underground estimate contains 2.178 million ounces of measured and indicated gold resources, with inferred resources reported separately. The historical Mupane inventory provides a Botswana reference, while the reported production at Vubachikwe, Jessie and Freda records gold already recovered from other parts of the Gwanda belt. The figures below retain their original dates and reporting categories. [1–3]

Table 1 Selected published information for regional gold mines

Mine or Deposit	Published Figures	Date and Reporting Basis
Blanket Gwanda belt	Underground M&I: 17.674 Mt at 3.83 g/t; 2.178 million oz. Inferred: 6.940 Mt at 3.35 g/t; 748,000 oz.	Effective 30 June 2026; 100% project basis. Underground resources include reserves. [1]
Mupane Tati belt	M&I: 5.166 Mt at 1.42 g/t; 235,800 oz. Inferred: 4.378 Mt at 1.35 g/t; 190,700 oz. P&P reserves: 1.810 Mt at 2.07 g/t; 120,200 oz.	Effective 31 December 2021; historical inventory. Resources exclude reserves. Main resource inventory excludes slimes and includes a small stockpile. [2]
Vubachikwe Gwanda belt	1.04 million oz of reported historical gold production.	Historical production account reproduced in the 2017 Blanket technical report. [3]
Jessie Gwanda belt	12 tonnes of reported historical gold production, approximately 386,000 oz.	Historical production account reproduced in the 2017 Blanket technical report. [3]
Freda Gwanda belt	7,550 kg of reported historical gold production, approximately 243,000 oz.	Historical production account reproduced in the 2017 Blanket technical report. Freda in Gwanda, distinct from Freda Rebecca. [3]

M&I = measured and indicated; P&P = proven and probable; Mt = million tonnes; oz = troy ounces. Inferred resources are shown separately. Production, resources and reserves describe different quantities and have not been combined. The Mupane figures are historical and do not represent a current remaining inventory; Golden Eagle is included in that inventory. Mineral resources that are not mineral reserves do not have demonstrated economic viability.

The regional information is drawn from the cited third-party disclosures; the older production accounts are historical reports, rather than current resource estimates. Mineralization and economic results at these properties are not necessarily indicative of mineralization or economic potential at Vumba. Their relevance is to the regional geological setting and the history of gold exploration and mining.

Figure 1 Regional greenstone belts and gold mines

The enlarged Maitengwe–Vumba panel places the two projects in their geographic setting. Maitengwe’s reported 580.75 km² project area is a landholding measure. The approximately 39 km north–south survey extent and approximately 68 km north–south span from the northern edge of the Maitengwe survey footprint to Vumba Central are geographic distances, not demonstrated mineralized strike lengths. Geological outlines, mine positions and the digitized survey footprint are generalized; the survey outline is not a surveyed license boundary. Insets have separate scales. Source credits are shown on the map; Maitengwe survey coverage is from the Company’s 14 October 2026 announcement. [4]

Exploration History and Historical Drilling

Documented modern exploration at Vumba began in 2005 with surface prospecting and sampling of old workings and dumps. Soil sampling and trenching during 2006 and 2007 included 7,464 soil samples and 33 trenches. Between 2006 and 2009, historical drilling comprised 110 reverse circulation holes totaling 6,749 m and nine diamond holes totaling 1,180 m. Ground induced polarization and magnetic surveys were undertaken in 2008.

One Bullion completed further surface work and regional targeting during 2019-2021, followed by 16 diamond holes totaling 3,589.6 m in 2022. A high-resolution airborne geophysical survey completed in July 2026 added information on rock packages, contacts and structures. A new diamond drilling program commenced in August 2026.

These campaigns provide both broad reverse circulation intersections and narrower high-grade diamond-core samples. They are evidence of gold at the tested positions and provide reference points for the current interpretation. Selected historical results are shown below; the variation in grade and interval length is part of the geological question being investigated. [5]

Table 2 Selected historical drilling results at Vumba

Hole or Interval	Drill Program	From (m)	To (m)	Length (m)	Gold (g/t)
SR004	RC	37.00	47.00	10.00	2.18
SR033	RC	16.00	42.00	26.00	2.60
SR083	RC	0.00	28.00	28.00	1.47
SR083 including	RC	9.00	16.00	7.00	1.91
SR083 including	RC	18.00	28.00	10.00	2.47
SR084	RC	30.00	47.00	17.00	1.41
SR084 including	RC	43.00	46.00	3.00	4.65
SR085	RC	51.00	64.00	13.00	2.02
SD071	DD	39.00	52.00	13.00	8.52
SD071 including	DD	42.00	43.00	1.00	101.81
SD070	DD	13.32	13.55	0.23	14.76
SD074	DD	89.33	90.00	0.67	7.47
SD076	DD	95.00	96.10	1.10	4.19
VUDD005	DD	23.00	24.00	1.00	20.90
VUDD016	DD	58.00	59.00	1.00	15.25

RC = reverse circulation; DD = diamond drilling. All lengths are downhole; true widths are unknown. “Including” rows lie within the preceding parent interval and are not additional meters. Reported composites are length-weighted averages that include lower-grade internal samples. Gold grades are rounded to two decimal places. The SD071 composite is strongly influenced by the 1.0 m sample at 101.81 g/t gold. The VUDD005 and VUDD016 results shown use the reported gravimetric determinations.

The broader RC intersections include SR033 at Makoba and the SR004 and SR083–SR085 results in the North area. Their distribution gives the Company several positions from which to evaluate the relationship between mineralization, host rocks and structure. The high-grade sample within SD071 is reported alongside its enclosing interval so that its influence on the composite is clear.

Surface Results and Geological Interpretation

Historical trenching adds surface observations to the drill record. The results range from longer, lower-grade intervals to short high-grade sections, including VUT004. Together with geological mapping and the drill data, these observations help locate gold-bearing positions and assess their relationship to the surrounding rocks. Selected results are shown in Table 3. [5]

Table 3 Selected historical trenching results at Vumba

Trench or Interval	From (m)	To (m)	Length (m)	Gold (g/t)
ST013	142.00	146.00	4.00	3.14
ST017	0.00	20.00	20.00	0.85
ST025	62.00	72.00	10.00	1.84
VUT004	70.00	73.50	3.50	18.79
including VUT004	71.00	73.50	2.50	26.12
VUT005	85.10	86.00	0.90	9.88

From and to positions are measured along the trench. Sampled lengths are not established true widths. VUT004’s included 2.5 m interval uses the reported gravimetric assays; the 3.5 m parent interval also includes the adjoining 1.0 m sample grading 0.469 g/t gold. These are selected results and do not represent the average grade of the property.

Relating Known Gold Occurrences to the Airborne Data

The high-resolution airborne survey completed in July 2026 provides a common geophysical framework for comparing these historical occurrences. Magnetic patterns help trace rock packages, contacts and structural breaks, including features that may be difficult to follow from surface observations alone. The Company is assessing where the known gold-bearing positions coincide with those features and where similar geological settings warrant further testing. Magnetic response does not measure gold grade.

Figure 2 presents the first vertical derivative of reduced-to-pole magnetic data with hillshade and identifies four descriptive areas: North, Marula, Makoba and the southern Somerset / New Zone grouping. North includes the SR004–SR006 and SR083–SR086 area; Marula includes SR041, SR043 and SD076; and Makoba includes SR033 and SR088. The southern grouping includes Somerset, New Zone and the vicinity of VUDD016. It remains a provisional grouping for interpretation.

The four areas bring the historical evidence into a broader map presentation and are distinct from the three priority structural corridors identified for the initial 2026 drilling program. Their outlines organize the observations for further investigation; continuity within or between the areas has yet to be established. The Company is also integrating geological logs and multi-element geochemistry to assess gold associations with arsenic and sulfide mineralization and to distinguish host-rock packages.

This work will help define follow-up drilling to test specific geological relationships, including the orientation of mineralized structures, the position of higher-grade zones and the persistence of mineralization between existing drill holes and surface occurrences. Those questions connect the historical results to the next phase of exploration.

Figure 2 Vumba magnetic interpretation and historical gold occurrences

First vertical derivative of reduced-to-pole magnetic data with hillshade. Circles mark projected positions of selected assay intervals; squares mark gold-bearing collars where interval positions are unavailable. Dashed outlines are schematic interpretation guides and do not establish mineralized boundaries, true widths or continuity. The southern grouping is provisional. Base-image alignment and projected positions are approximate. Coordinates are WGS 84 / UTM zone 35S, shown in kilometers. Source: the Vumba project map and underlying exploration records.

Current Program and Next Steps

The 2026 diamond drilling phase has tested the Central and North Main areas. VUDD017 and VUDD018 were completed at Central, and VUDD019 tested North Main to a downhole depth of 315 m. The program has added core and geological observations to the historical exploration record.

During November, drilling is paused while the Company completes logging and sampling of existing core, progresses laboratory and check-assay work, and reviews the geological model. This includes the core from VUDD018 through VUDD020. The findings will guide the selection and sequencing of further work. Reverse circulation drilling is being considered for the next phase, with the scope and timing to be determined following the review.

The review will bring the new core observations, analytical work and airborne interpretation together with the historical drill and trench results. The next drilling decisions will depend on how consistently the observed geology and assays support the proposed structures and target areas. The aim is to improve the geological model and select follow-up tests that can establish the orientation and continuity of mineralization.

Analytical results from the 2026 program will be reported separately following the relevant technical review. The historical results in this release provide context for that work; further exploration is required to establish continuity, true widths and potential economic significance.

Historical Sampling and Data Verification

The historical results have been compiled from the Vumba exploration database, supporting assay records and the technical report effective April 27, 2025. The historical results and associated quality assurance and quality control information used in this compilation have been checked.

The assay database records gold analyses using Au-AA23, with Au-GRA21 gravimetric determinations where applicable. Drill and trench composites are calculated using length-weighted averages of the samples within the stated intervals. Primary and repeat determinations are not combined as additional sample lengths.

Further information on the exploration history and historical methods is available in the Company’s Technical Report on PL153/2016 in the Vumba Greenstone Belt, Botswana, effective April 27, 2025, including Sections 6, 9 and 10. This release does not report a mineral resource estimate or an economic assessment for Vumba.

Qualified Person

The scientific and technical information in this news release has been reviewed and approved by Tim Raymond, Pr.Sci.Nat., a Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects (NI 43-101). Mr Raymond provides independent geological consulting services to the Company through RAYMEX (Pty) Ltd and has conducted site visits to the Vumba Gold Project.

The Company also announced today that it issued the previously announced shares to SLD Capital Corp for September services for an aggregate of 75,484 Common Shares and 97,125 for October. All Common Shares issuable under their approved agreement will be subject to a statutory hold period of four months and one day from the date of issuance.

About One Bullion

One Bullion Ltd. (TSXV: OBUL) is a Toronto-based gold exploration company focused on advancing high-quality gold assets in Botswana, one of Africa’s stable and established mining jurisdictions. Established in 2018, the Company controls approximately 8,004 km² of prospective land across three greenstone belt-hosted gold projects, including Vumba, Kraaipan and Maitengwe. One Bullion’s strategy centers on disciplined, data-driven exploration combining modern geological methods with advanced targeting to identify and test high-priority gold targets while maintaining a commitment to environmental stewardship, community engagement and long-term value creation for stakeholders.

Forward-Looking Information

This news release contains forward-looking information concerning geological interpretation, target evaluation, the completion of logging, sampling and analytical work, the timing of results, potential use of reverse circulation drilling and future exploration at Vumba. Such information reflects the Company’s current expectations and depends on assumptions concerning geological interpretations, funding, permits, access, personnel, contractors and laboratory capacity. Risks include unfavorable assay results, changes in geological interpretation, drilling and sampling difficulties, delays, costs and conditions affecting operations in Botswana. Actual results and work programs may differ materially. There is no assurance that further exploration will establish continuous or economic mineralization. Readers should not place undue reliance on forward-looking information. Except as required by applicable law, the Company undertakes no obligation to update this information.

Contact Information:
Adam Berk, Chief Executive Officer
OneBullion@KCSA.com

Investor Contact:
KCSA Strategic Communications
Jack Perkins or Valter Pinto
T: 212-896-1254
OneBullion@KCSA.com

Sources For Regional Information and Exploration Background

[1] Caledonia Mining Corporation, Blanket Mine resource update, announced 28 August 2026, effective 30 June 2026. Underground resource statement and reporting notes.

[2] Galane Gold Ltd., Annual Information Form dated 28 April 2022, printed pages 13–14. Mupane mineral resources and reserves effective 31 December 2021.

[3] Minxcon, 2017 technical report on the Blanket Mine, Item 22, Adjacent Properties. Historical production descriptions for Vubachikwe, Jessie and Freda.

[4] One Bullion, One Bullion Receives Final Maitengwe Airborne Geophysical Dataset and Provides Vumba Drilling Update, 14 October 2026. Regional survey coverage and dated drilling background.

[5] One Bullion, Technical Report on PL153/2016 in the Vumba Greenstone Belt, Botswana, effective 27 April 2025, including Sections 6, 9 and 10. Historical results also draw on the Company’s exploration database and supporting assay records.

Figure 1 retains the original map credits: MSA (2011), Minxcon (2022), Zhai et al. (2006), Bineli-Betsi et al. (2020), One Bullion (14 October 2026) and Natural Earth. Figure 2 is based on the Vumba project map and historical exploration data.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/368391ee-246b-4191-8c70-ff5a6dfecff6

https://www.globenewswire.com/NewsRoom/AttachmentNg/ac11fa16-5065-4613-9235-dd1e5b086c51

CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT

NEW YORK and TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of novel serotonergic agonists (“NSAs”), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference taking place in Boston.

The fireside chat will be webcast live on Monday, November 9, 2026 at 3:00 p.m. EDT.

To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma’s investor relations website.

About Helus Pharma

Helus Pharma is a clinical stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s anticipated participation at the Guggenheim Healthcare Innovation conference; and plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company’s operations; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three months ended June 30, 2026, and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca/ and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com

Greg Cavers
Chief Financial Officer
Helus Pharma
1-866-292-4601 x715
irteam@helus.com – or – media@helus.com

Media Contact:
Charlotte Wray
CEO
RXMD
(646) 247-3405
cwray@rxmedyn.com

Business will operate as Biomark Scientific, a leader in accessible, scalable and automated genomic workflows powered by proprietary microfluidics technology

BOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Global private equity healthcare specialist ARCHIMED, and Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools”), today announced the completion of ARCHIMED’s previously announced acquisition of Standard BioTools’ Microfluidics Business. As part of ARCHIMED, the business enters its next chapter as a standalone business under the name Biomark Scientific.

Biomark Scientific, an innovative microfluidics technology tools provider specializing in high-throughput and multi-assay genomics systems, will offer versatile and scalable genomic profiling on its flagship Biomark™ platform. The next-generation Biomark X9 system is the only automated PCR, qPCR and NGS library prep system on the market, performing simultaneous profiling of multiple types of genomic assay readouts in a single run using patented integrated fluidic circuits (IFCs).

A highly regarded brand in high-throughput genomic workflows serving research institutions, public health laboratories and biobanks, Biomark was previously part of Fluidigm, which was founded in 1999 and renamed Standard BioTools in 2022. As Biomark Scientific, the business will continue to offer its automated bench-top system that can run genomics assays with robustness, speed and precision, driving quality insights for critical, time-sensitive data.

Within ARCHIMED, Biomark Scientific plans to build on its established technology, expertise and deep customer relationships, while expanding its capabilities and supporting scientific discovery across genomics, clinical research and public health. The company will be an independent entity comprised of the same dedicated team and supported by enhanced capabilities to provide seamless continuity of the products and services that customers and partners trust.

“This is an exciting step forward for our organization, strengthening our ability to serve and support our customers and partners,” says Luke Stewart, newly appointed Chief Commercial Officer of Biomark Scientific. “Together with ARCHIMED, expanding our resources and investing in our expertise reflects our continued commitment to delivering greater value to our customers, with the reliability and quality they depend on. This partnership enables us to confidently move into this next phase while staying true to our foundation of scientific excellence and exceptional service, all in support of advancing genomics and improving public health.”

“With Biomark Scientific’s accelerating position in the clinical research and public health markets, we are poised to support the company in fortifying global growth and launching the business as a primary player in the industry,” says Michael Goetter at ARCHIMED. “Biomark Scientific is comprised of an amazing team, well-positioned to maintain their current momentum with the rigor and meticulous drive that has instilled loyalty among the genomics community.”

About ARCHIMED

With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €15 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

About Standard BioTools Inc.

Standard BioTools Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Standard BioTools’ established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/notices. Trademarks: standardbio.com/legal/terms-and-conditions/.

Patent and License Information: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. All rights reserved.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the disposition of Standard BioTools’ Microfluidics Business. The words “strengthen,” “support,” “expand,” “invest,” “enable,” “accelerate,” “advance,” “improve,” “aim,” “create,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) the future conduct and growth of the Microfluidics Business and the markets in which ARCHIMED operates; (ii) the success of products and services competitive with the Microfluidics Business; (iii) ARCHIMED’s ability to successfully integrate the Microfluidics Business into its existing operations and the Microfluidics Business’s technology and products into its portfolio; (iv) ARCHIMED’s ability to sell the products and further develop the Microfluidics Business’s technology; (v) ARCHIMED’s ability to successfully manage partner and customer relationships in the market; and (vi) customer uptake of, and satisfaction with, new products and services.

For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2026, Standard BioTools’ most recent Quarterly Report on Form 10-Q and Standard BioTools’ other filings with the SEC. Should any of these risks or uncertainties materialize, actual results could differ materially from expectations. These forward-looking statements speak only as of the date hereof. Standard BioTools does not assume any obligation to, and does not currently intend to, update any such forward-looking statements except as may be required by law.

Additional Information and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed transactions involving Standard BioTools and Treeline Biosciences, Inc. (“Treeline”) and/or Standard BioTools’ sale of its Mass Cytometry business to Element Biosystems, LLC (“Element”). In connection with the Treeline transaction and related stockholder vote, Standard BioTools has filed with the SEC a registration statement on Form S-4, as amended (the “Form S-4”), which was declared effective by the SEC on October 21, 2026. The Form S-4 includes a definitive proxy statement and a definitive prospectus of Standard BioTools. The definitive proxy statement/prospectus, dated October 21,2026, was first mailed to stockholders of Standard BioTools on or about October 21, 2026. This communication is not a substitute for the definitive proxy statement/prospectus or any other document that Standard BioTools may file with the SEC or send to its stockholders in connection with the proposed transactions. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

INVESTORS AND STOCKHOLDERS OF STANDARD BIOTOOLS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS, SUPPLEMENTS AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND OTHER RELEVANT MATERIALS FILED OR TO BE FILED WITH THE SEC BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED TRANSACTIONS BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT STANDARD BIOTOOLS, TREELINE, ELEMENT AND THE PROPOSED TRANSACTIONS. Copies of the materials filed or to be filed by Standard BioTools with the SEC may be obtained free of charge on Standard BioTools’ Investor Relations website at https://investors.standardbio.com or by contacting Standard BioTools’ Investor Relations department at ir@standardbio.com. In addition, all of those materials are available at no charge on the SEC’s website at www.sec.gov.

Participants in the Solicitation

Standard BioTools, Treeline and certain of their respective directors, executive officers, other members of management and employees may be deemed to be participants in the solicitation of proxies of Standard BioTools stockholders in connection with the proposed transactions under SEC rules. Investors and stockholders may obtain more detailed information regarding the names, affiliations and interests of Standard BioTools’ executive officers and directors who may, under SEC rules, be deemed participants in the solicitation by reading Standard BioTools’ proxy statement for its 2026 annual meeting of stockholders (including under the headings “Management and Corporate Governance,” “Executive Officer and Director Compensation,” “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,” “Executive Compensation” and “Certain Relationships and Related Transactions, and Director Independence”), its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and Standard BioTools’ other filings with the SEC. Information regarding Treeline’s directors and executive officers who may be deemed participants in the solicitation is contained in the proxy statement/prospectus filed by Standard BioTools. These documents are available free of charge at the SEC’s website at www.sec.gov or by going to Standard BioTools’ Investor Relations website at http://investors.standardbio.com or contacting Standard BioTools’ Investor Relations department at ir@standardbio.com.

Contacts:

Standard BioTools:

IR:
ir@standardbio.com

Media:
Dan Moore / Nick Lamplough / Tali Epstein
Collected Strategies
LAB-CS@collectedstrategies.com

ROCKVILLE, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in two upcoming investor conferences in London, United Kingdom.

UBS Global Biopharma Conference

Format: Company presentation and one-on-one investor meetings

Date and Time: Monday, November 16, 2026, 4:40 p.m. to 5:10 p.m. GMT (11:40 a.m. to 12:10 p.m. ET)

Location: Rosewood London, 252 High Holborn, London, UK

2026 Jefferies Global Healthcare Conference in London

Format: Company presentation and one-on-one investor meetings

Date and Time: Tuesday, November 17, 2026, 9:00 a.m. to 9:25 a.m. GMT (4:00 a.m. to 4:25 a.m. ET)

Location: The Waldorf Hilton, Aldwych, London, UK

Investors interested in scheduling a meeting with the Ascentage Pharma management team should contact their conference representative.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations:

Sumedh Sunkaraneni
Ascentage Pharma
IR@ascentage.com
+1 (301) 792-6286

Brian Korb
astr partners
brian.korb@astrpartners.com
+1 (917) 653-5122